Wealthspire Advisors (Maryland)’s Ligand Pharmaceuticals LGND Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,052	Closed	-$82K	–	1309
2019 Q1	$82K	Buy	1,052 +454	+76%	+$34.4K	0.01%	712
2018 Q4	$51K	Sell	598 -14	-2%	-$1.49K	﹤0.01%	851
2018 Q3	$105K	Buy	612 +9	+1%	+$1.36K	0.01%	669
2018 Q2	$78K	Buy	603 +100	+20%	+$11.2K	0.01%	806
2018 Q1	$52K	Buy	503 +88	+21%	+$8.7K	﹤0.01%	964
2017 Q4	$35K	Buy	415 +98	+31%	+$8.49K	﹤0.01%	1144
2017 Q3	$27K	Buy	317 +245	+340%	+$19.4K	﹤0.01%	1197
2017 Q2	$5K	Buy	+72	New	+$5.04K	﹤0.01%	1769

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s LGND Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 1,052 shares — an estimated $82K sold.

Wealthspire Advisors (Maryland) first reported a position in LGND in Q2 2017 and held it in 8 quarters. The position peaked at $105K in Q3 2018. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Wealthspire Advisors (Maryland) reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 1,052 Ligand Pharmaceuticals shares in Q2 2019, an estimated $82K.
Wealthspire Advisors (Maryland) first reported a position in Ligand Pharmaceuticals in Q2 2017 and held it in 8 quarters.
Wealthspire Advisors (Maryland)'s Ligand Pharmaceuticals position peaked at $105K in Q3 2018.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.